Accessibility Menu
Clinuvel Pharmaceuticals logo

Clinuvel Pharmaceuticals

(OTC) CLVLF

Current Price$8.45
Market Cap$424.05M
Since IPO (2003)+3,769%
5 Year-60%
1 Year+11%
1 Month+0%

Clinuvel Pharmaceuticals Financials at a Glance

Market Cap

$424.05M

Revenue (TTM)

$187.86M

Net Income (TTM)

$71.31M

EPS (TTM)

$0.41

P/E Ratio

20.30

Dividend

$0.03

Beta (Volatility)

0.14 (Low)

Price

$8.45

Volume

8

Open

$8.45

Previous Close

$8.45

Daily Range

$8.45 - $8.45

52-Week Range

$6.81 - $8.60

CLVLF News

No articles available.

CLVLF: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clinuvel Pharmaceuticals

Industry

Biotechnology

CEO

Lachlan Hay

Headquarters

Melbourne, VIC 3000, AU

CLVLF Financials

Key Financial Metrics (TTM)

Gross Margin

64%

Operating Margin

39%

Net Income Margin

34%

Return on Equity

14%

Return on Capital

15%

Return on Assets

12%

Earnings Yield

4.93%

Dividend Yield

0.00%

Payout Ratio

7.70%

Stock Overview

Market Cap

$424.05M

Shares Outstanding

50.18M

Volume

8

Short Interest

0.00%

Avg. Volume

35.267

Financials (TTM)

Gross Profit

$79.14M

Operating Income

$45.73M

EBITDA

$57.20M

Operating Cash Flow

$41.10M

Capital Expenditure

$298.57K

Free Cash Flow

$40.80M

Cash & ST Invst.

$224.11M

Total Debt

$528.53K

Clinuvel Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$36.92M

+12.5%

Gross Profit

$20.74M

+22.6%

Gross Margin

56.19%

N/A

Market Cap

$424.05M

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

$10.44M

-4.5%

EBITDA

$11.45M

-46.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$232.57M

+34.1%

Accounts Receivable

$16.58M

+26.8%

Inventory

$8.41M

-33.0%

Long Term Debt

$34.48K

-95.2%

Short Term Debt

$306.47K

-13.9%

Return on Assets

12.07%

N/A

Return on Invested Capital

15.06%

N/A

Free Cash Flow

$12.37M

-41.3%

Operating Cash Flow

$12.52M

-52.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTCHFPureTech Health plc
$1.55-3.13%
CYDYCytoDyn Inc.
$0.28+3.66%
NWBONorthwest Biotherapeutics, Inc.
$0.22+2.27%
CMVLFCellectis S.A.
$4.50+2.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.66-0.02%
TAT&T
$28.36+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$77.43+0.02%
IBITiShares Bitcoin Trust
$39.87+0.00%

Questions About CLVLF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.